It’s that time of year where there seems to be a countdown for everything – Top 100 Songs, Top Baby Names, Top 10 Sports Moments of 2019 – We wanted to get in on the fun too and here it is… Top 5 Coronary IVL Publications from 2019!
2019 was a big year for us, we celebrated our first full year of having the Shockwave C2 IVL catheter on the market and with that came increasing real-world use. The breakout moment seemed to be EuroPCR where there 40+ presentations on IVL, and it didn’t stop with the podium. We also saw an increase in coronary IVL related publications from 10 in 2018 to 36 in 2019. Here are the ones we believe to be the Top 5:
5. Intravascular Lithotripsy for Calcific Coronary and Peripheral Artery Stenoses
This expert review article not only provides an overview of the technical features of IVL and the related clinical outcomes, it provides a comparison of different modalities used to treat calcified, coronary arteries.
4. Intracoronary Lithotripsy for the Treatment of Calcified Plaque
Similar to the previous publication, this one provides an overview of available clinical evidence, and then proceeds to discuss specific case scenarios in which IVL has a defined role, such as calcified bifurcation lesions.
3. Intravascular Lithotripsy in Calcified Coronary Lesions
This prospective, multi-center observational study was recently published demonstrating in the real-world scenario when IVL is used as a primary intervention in these moderate and severely calcified lesions, primary end point strategy success (stent expansion <20% residual stenosis) was achieved 84.6% of the time.
2. Shockwave Intravascular Lithotripsy for Calcified Coronary Lesions: First Real-World Experience
This early real-world experience was our first glimpse into outcomes when used in patients across a broad range of indications, include ACS and STEMI.
And the top publication for 2019 is ….
This publication provides the outcomes of the largest coronary IVL study that has been completed to date. The Disrupt CAD II Study was evaluating the safety and effectiveness of coronary IVL in more patients and more hospitals following CE Mark approval. The outcomes confirm the experience seen in Disrupt CAD I – high acute gain, low rates of complications. The mechanistic findings from OCT sub-study were also included in this must read of 2019!
We can’t wait to see what new publications are in store for 2020! Follow us on Twitter at @ShockwaveIVL or Contact Us on our website to keep up with the latest news.
Important Safety Information - Coronary
Caution: In the United States, Shockwave C2 Coronary IVL catheters are investigational devices, limited by United States law to investigational use. DISRUPT CAD III Study
Shockwave C2 Coronary IVL catheters are commercially available in certain countries outside the U.S. Please contact your local Shockwave representative for specific country availability. The Shockwave C2 Coronary IVL catheters are indicated for lithotripsy-enhanced, low-pressure balloon dilatation of calcified, stenotic de novo coronary arteries prior to stenting. For the full IFU containing important safety information please visit: https://shockwavemedical.com/clinicians/international/coronary/shockwave-c2/
